S ystemic lupus erythematosus (SLE)
3 is a multisystem autoimmune disease of unknown etiology that mainly affects women of childbearing age. One of the hallmarks of this disease is the loss of tolerance to self-Ags, particularly nuclear Ags (1) . This loss of tolerance leads to production of autoantibodies directed against nuclear Ags, such as chromatin, and results in the formation of immune complexes. Deposition of immune complexes in the glomeruli, skin, and other organs induces tissue damage resulting in the manifestations of disease, which include skin rash, arthritis, and glomerulonephritis (2) . Although the genes responsible for development of SLE in humans have not been clearly identified, there is convincing evidence that SLE has a strong, but complex, genetic basis (3) .
Identification of the immune abnormalities that lead to the development of SLE has been greatly aided by the study of lupusprone mouse strains. New Zealand Black (NZB) mice develop a lupus-like autoimmune disease characterized by production of antissDNA and anti-RBC Abs leading to hemolytic anemia (4) . Mapping studies have revealed that susceptibility to lupus in NZB mice is polygenic with multiple genes contributing to the generation of high affinity autoantibodies, nephritis, and mortality in various crosses (5) (6) (7) (8) (9) (10) (11) (12) (13) . In particular, genetic loci on NZB chromosome 1 have been shown in multiple crosses to play a prominent role in disease susceptibility (5, 7, 9, 10, 12, 13) . Indeed, in one cross between NZB and B6.H2 z mice, a region on distal NZB chromosome 1 was found, in combination with H2 z , to confer Ͼ90% of the susceptibility to nephritis and autoantibody production (9, 10) .
The presence of a lupus susceptibility gene(s) on distal NZB chromosome 1 was confirmed by Rozzo et al. (14) , who showed that B6 congenic mice with an NZB interval extending from ϳ79 to 109 cM, produced IgG anti-nuclear Abs. Three candidate genes have been proposed to contribute to the development of autoimmunity in this interval: Ifi202 (14) , Fcgr2b (15, 16) , and the SLAM/CD2 cluster (17) . However, work by ourselves and others (12, 13) suggested that it was unlikely that this interval contained all of the lupus susceptibility genes located on NZB chromosome 1. For example, Kono et al. (5) showed linkage between a NZB region around 67 cM and anti-chromatin Ab production and splenomegaly in a (NZB ϫ New Zealand White (NZW))F 2 intercross. In our mapping study of (B6 ϫ NZB)F 2 intercross mice, IgG anti-ssDNA Ab production was linked to a broad region on NZB chromosome 1 with 2 shallow lod score peaks at 63 and 92 cM, and a similar area of broad linkage was demonstrated for several B cell activation phenotypes, including increased expression of B7.1, B7.2, ICAM-1, and CD44 (13) . Indeed, the peak lod scores for IgG anti-ssDNA Ab production, ICAM-1, and CD44 were all located in the 63-76 cM region.
To investigate the presence of additional susceptibility genes on NZB chromosome 1, we generated congenic mice with NZB chromosome 1 intervals of various lengths and compared their cellular and autoimmune phenotype (18) . We found that mice with a congenic interval extending from ϳ35 to 106 cM had a significantly more severe autoimmune phenotype than mice with an interval extending from ϳ82 to 106 cM, confirming the presence of at least two independent lupus susceptibility loci on NZB chromosome 1. Mice with the shorter interval (labeled B6.NZBc1S in this article) had evidence of increased T cell activation with an increased proportion of memory T cells, whereas mice with the longer interval (B6.NZBc1L) had more robust T cell activation and an increased proportion of activated B cells. The increased T cell activation in B6.NZBc1L mice, as compared with B6.NZBc1S mice, was B cell dependent, leading us to hypothesize that the genetic locus located within the shorter interval predominantly affected T cell function while that located in the longer interval altered B cell function.
In this study, we have further investigated the nature and location of the immune abnormalities in these mice. By generating mixed hemopoietic radiation chimeras, we show that autoimmunity in B6.NZBc1L mice results from intrinsic B and T cell defects. We further show that the susceptibility locus located within the shorter interval leads to spontaneous activation of T cells with specificity for nucleosome histone components. Despite the presence of activated self-reactive T cells in mixed chimeric mice, tolerance in B6-derived B cells is sufficient to prevent autoantibody production because only congenic B cells produce antinuclear Abs. Thus, in mice with the shorter interval T and B cell defects must act together to produce the autoimmune phenotype. In mice with the longer NZB interval, autoimmunity is exacerbated by the presence of an additional susceptibility locus that leads to enhanced T and B cell activation through generation of a positive feedback loop. The data provide new insights into the nature of the immune defects that produce autoimmunity in NZB chromosome 1 congenic mice.
Materials and Methods

Mice
C57BL/6 (B6), C57BL/6.Thy1 a IgH a Gpi a (denoted here as B6.Thy1 a IgH a ), and B6.129S2-Tcra tm1Mom (B6.TCR␣ Ϫ/Ϫ ) breeders were purchased from The Jackson Laboratory. NZB mice were purchased from Harlan Sprague Dawley. Congenic mice were produced by backcrossing mice with NZB chromosome 1 intervals onto the B6 background, using the speed congenic technique. Mice were typed at each successive generation using polymorphic microsatellite markers that discriminate between NZB and B6 DNA. Markers were spaced at ϳ20 cM intervals throughout the genome, except for regions containing lupus susceptibility genes where more densely spaced markers were used. Fully backcrossed mice were obtained in six to seven generations and intercrossed to produce congenic mice that were homozygous for NZB chromosome 1 intervals. Mice used in this study, denoted B6.NZBc1L and B6.NZBc1S for simplicity, correspond to the B6.NZBc1 (35-106) and B6.NZBc1 (85-106) mice published previously (18) . B6.NZBc1L and B6.NZBc1S mice have introgressed NZB intervals extending from between D1Mit21 (32.8 cM) and D1Mit303 (34.8 cM) or D1Mit396 (79 cM) and D1Mit159 (81.6 cM) to between D1Mit223 (106 cM) and D1Mit210 (109 cM). The borders of these intervals have been refined from our previous publication by identification and testing of additional polymorphic primers. B6.NZBc1L and B6.NZBc1S mice expressing transgenes encoding IgM/IgD H and L chains specific for hen egg white lysozyme (anti-HEL Ig transgenic (Tg), MD4; Ref. 19 ) were produced by backcrossing the anti-HEL Ig transgene from B6 anti-HEL Ig Tg mice (purchased from The Jackson Laboratory). Offspring were genotyped by PCR, using primers specific for the V region of the Ig H chain. B6.NZBc1L.TCR␣ Ϫ/Ϫ mice were produced by backcrossing the gene deletion onto the B6.NZBc1L background and then intercrossing to produce knockout mice. TCR␣ knockout mice were genotyped by PCR, using neoand TCR␣-specific primers. The mice were housed in microisolators in the animal facility at the Toronto Western Hospital and were specific-pathogen free. All of the mice used in this study were female.
Generation of bone marrow reconstituted and mixed chimeric mice
For bone marrow reconstitution experiments, 6-to 8-wk-old female B6.Thy1 a IgH a recipient mice were put on sterilized acid water at least 1 wk before reconstitution. On the day of cell transfer, recipient mice were given two doses of gamma radiation (525 rad) separated by 2 h and injected, through the tail vein, with 1 ϫ 10 7 T cell-depleted bone marrow cells from B6 or B6.NZBc1L mice. For mixed chimeras, 6-to 8-wk-old female B6 mice were treated, as above, and injected with a mixture of T cell-depleted bone marrow from B6.Thy1 a IgH a mice and B6 or B6.NZBc1L mice at a ratio of 3:1 or 1:1. Recipients were sacrificed and analyzed 4 or 7 mo later.
Flow cytometry analysis
RBC-depleted splenocytes (5 ϫ 10 5 ) were incubated with 10 g/ml mouse IgG (Sigma-Aldrich) for 15 min to block FcRs and stained with various combinations of directly conjugated mAbs. Following washing, allophycocyanin-conjugated streptavidin (BD Pharmingen) was used to reveal biotin-conjugated Ab staining. Dead cells were excluded by staining with 0.6 g/ml propidium iodide (Sigma-Aldrich). Flow cytometry of the stained cells was performed using a dual laser FACSCalibur (BD Biosciences) and analyzed using CellQuest (BD Biosciences) software. Live cells were gated on the basis of propidium iodide uptake and scattering characteristics with 10,000 events being acquired for each sample. The following directly conjugated mAbs were purchased from BD Pharmingen: biotin anti-CD11c (N418), biotin anti-CD11b (Mac1), biotin anti-CD4 (L3T4), biotin anti-CD8 (53-6.7), biotin anti-CD62L (MEL-14), biotin anti-B220 (RA3-6B2), biotin anti-Thy1.1 (HIS51), biotin anti-Thy1.2 (53-2.1), biotin anti-IgM
, FITC anti-TCR␤ (H57-597), and FITC anti-TCR␦␥ (GL3). FITC anti-CD62L was purchased from Cedarlane Laboratories. Biotinylated HEL was prepared using an EZ-Link Sulfo-NHS-LC Biotinylation kit (Pierce). All isotype controls, with the exception of hamster IgG controls (BD Pharmingen), were purchased from Cedarlane Laboratories.
APC isolation
Single-cell suspensions of splenocytes were isolated from 2-to 3-mo-old B6 mice by pressing through a nylon mesh. RBCs were removed by lysis in Geys' solution. The cell suspension was then incubated with purified anti-Thy1.2 (HO-13-4) and anti-CD4 (GK1.5) mAb followed by guinea pig complement (Cedarlane Laboratories) to remove T cells. Following lysis, the resultant cell population (Ͻ1% CD4 ϩ T cell contamination) was resuspended in RPMI 1640 containing 0.5% normal mouse serum (NMS).
CD4 ϩ T cell isolation
Single-cell suspensions of RBC-depleted splenocytes were suspended in 2% FBS/PBS and incubated with biotinylated anti-B220, -I-A d , -CD8, -Mac1, -CD11c, and -CD24 Abs on ice for 30 min. Excess Abs were removed by washing, and the cells were then resuspended in 2% FBS/PBS at a concentration of 100 ϫ 10 6 cells/ml. Streptavidin-conjugated Dynabeads (M-280; Dynal Biotech) were washed with 2% FBS/PBS to remove azide and resuspended at 160 ϫ 10 6 beads/ml in PBS. An equal volume of washed Dynabeads was added to the cell suspension and incubated at room temperature for 1 h. CD4 ϩ T cells were then purified by negative selection with a magnet and resuspended in 0.5% NMS/RPMI 1640. The resultant cell population contained Ͼ80% CD4 ϩ T cells.
T cell proliferation and cytokine assays
T cell-depleted splenic APCs, isolated from B6 mice, were irradiated with 2000 rad and then incubated for 1 h at 37°C with medium alone or containing 1 g/ml bovine total histones, H1, H2A, H2B, H3, or H4 (Roche). Excess Ag was removed by washing with PBS, and the cells were resuspended in 0.5% NMS/RPMI 1640. Ag-pulsed APCs were cultured at 0.5 ϫ 10 6 cells/well together with purified CD4 ϩ T cells (0.5 ϫ 10 6 per well) for 48 h at 37°C in 96-well flat-bottom plates. Anti-CD3 (5 g/ml) or Con A (5 g/ml) were added to control wells at the time of plating. Proliferation was measured by [ 3 H]thymidine incorporation after a 16-h pulse with 1 Ci/well. Uptake of [ 3 H]thymidine was quantified by a scintillation counter and expressed as mean counts per minute Ϯ SD of triplicate wells. For each Ag condition, a stimulation index was calculated by dividing the mean counts per minute in the presence of Ag by the mean counts per minute in the absence of Ag.
IL-4 and IFN-␥ levels in tissue culture supernatants were measured at 48 h. Anti-IL-4 and -IFN-␥ capture Abs, biotinylated-anti-IL-4 and -IFN-␥ detection Abs, and rIL-4 and IFN-␥ were purchased from BD Pharmingen. Assays were performed as per the manufacturer's recommendations. The concentration of cytokine in each supernatant was calculated from a standard curve with log-log plot of absorbance vs concentration of recombinant cytokine preparation.
Measurement of Ab production
Levels of IgM, IgM a , IgM b , IgG, IgG2a, IgG2a a , and IgG2a b antichromatin and -ssDNA Abs in the sera were measured by ELISA. ssDNA was prepared by boiling dsDNA (isolated from calf thymus DNA) for 10 min and quick cooling on ice. H1-stripped chromatin was prepared from chicken RBCs as described previously (20) . ELISA plates were coated overnight with either ssDNA (20 g/ml) or chromatin (8 g/ml) in PBS, washed with 0.05% Tween 20/PBS, and blocked with 2% BSA/PBS for 1 h at room temperature. After washing, serum samples were diluted 1/100 in 2% BSA/0.05% Tween 20/PBS, added to ELISA plates, and incubated for 1 h at room temperature. The presence of bound Abs was detected by adding alkaline-phosphatase-conjugated anti-IgM, -IgG, or -IgG2a (Caltag Laboratories) as secondary reagents. For allotype-specific ELISAs, biotinylated anti-IgG2a a and -IgG2a b , or -IgM a and -IgM b mAb (BD Pharmingen) were used and detected with alkaline-phosphatase-conjugated streptavidin (BD Pharmingen). To control for differences in the ability of the allotype-specific Abs to detect bound Ab, control sera were run on each assay that were of "a" (MRL/lpr/lpr) or "b" (B6.NZBc1L) allotype, and the results for allotype-specific assays were normalized to those seen with assays using anti-IgG2a or -IgM Abs that detected both allotypes.
Immunofluorescence staining of tissue sections
Spleens were snap frozen in OCT compound (Sakura Finetek) at the time of sacrifice. Cryostat sections (5 m) were fixed in acetone, washed with PBS, and blocked with 5% normal goat serum/PBS. Sections were stained with biotinylated peanut lectin (agglutinin) (PNA) (Sigma-Aldrich) with or without FITC anti-CD21 to detect germinal centers. For allotype-specific Ab staining of germinal centers, sections were stained with biotinylated anti-IgM a , -IgM b , -IgG2a a , or -IgG2a b mAb together with FITC anti-CD21. Biotin staining was revealed using rhodamine-conjugated streptavidin as a secondary reagent (Molecular Probes). Stained sections were mounted with Mowiol (Calbiochem) and tissue fluorescence visualized using a Zeiss Axioplan 2 imaging microscope (Zeiss). Digital images were obtained using the manufacturer's imaging system. Germinal centers were scored as positive for IgM a , IgM b , IgG2a a , and IgG2a b cells, when one or more cells could be clearly localized to the PNA ϩ region of the germinal center using CD21 staining to align serial sections. Cells that stained with anti-allotype Ab but were CD21 bright , and thus likely to be follicular dendritic cells, were excluded from the analysis.
Statistics
Comparisons of differences between groups of mice were performed using a Mann-Whitney U nonparametric test with the exception of IFN-␥ levels where a Wilcoxon two-sample test was used. Values of p Ͻ 0.05 were considered to be significant.
Results
Reconstitution of B6 mice with bone marrow cells from B6.NZBc1L mice transfers the autoimmune phenotype
To determine whether the genetic polymorphism(s) leading to autoimmunity in B6.NZBc1L mice affect bone marrow-derived immune cell populations, bone marrow cells from B6.NZBc1L (Thyl b IgH b ) or normal B6 (Thyl b IgH b ) mice were injected into lethally irradiated B6.Thyl a IgH a mice, and the recipients were analyzed 6 mo postreconstitution. In these mice, the majority of T and B cells were derived from the donor bone marrow (%IgM bϩ B220 ϩ cells Ͼ 90%; %Thy1 bϩ CD4 ϩ cells Ͼ 90%). In B6.NZBc1L mice, autoimmunity is characterized by increased production of IgG anti-ssDNA and -chromatin Abs, together with markers of increased T and B cell activation (18) . As shown in Table I , 6-mo-old B6.NZBc1L mice analyzed in tandem with reconstituted mice had the same phenotype that we have previously reported for 4-mo-old mice, including splenomegaly, increased proportions of activated (CD69 ϩ ) and costimulatory molecule expressing B cells, and increased proportions of activated (CD69 ϩ ) and memory (CD44 high CD62L low ) CD4 ϩ cells (18) . All of these phenotypes were recapitulated in mice reconstituted with B6.NZBc1L bone marrow. Transfer of B6.NZBc1L bone marrow also resulted in the same altered distribution of peripheral B cell subsets as seen in B6.NZBc1L mice, with increased proportions of CD21 low CD23 low and follicular B cells, and decreased proportions of T2 and marginal zone B cells (data not shown). As in our previous study, the increased costimulatory molecule expression was restricted to (for B7.1), or predominantly in (for B7.2 and ICAM-1), the CD21 low B cell population (Table I and data not shown). Mice reconstituted with B6.NZBc1L bone marrow also had significantly elevated levels of IgG anti-chromatin (OD Ϯ SD; B6.NZBc1L ϭ 0.371 Ϯ 0.261, B6 ϭ 0.006 Ϯ 0.002, p ϭ 0.017) and -ssDNA Abs (OD Ϯ SD; B6.NZBc1L ϭ 0.224 Ϯ 0.159, B6 ϭ 0.018 Ϯ 0.019, p ϭ 0.033), as compared with mice reconstituted with B6 bone marrow. Thus, the immune defects leading to abnormal lymphocyte activation and autoantibody production in NZB chromosome 1 congenic mice affect bone marrow derived cell populations. 
B6.NZBc1L mice have intrinsic B and T cell functional defects
To investigate the roles of intrinsic B and T cell functional abnormalities in production of the autoimmune phenotype in NZB chromosome 1 congenic mice, chimeric mice with a mixture of bone marrow from B6. (Fig. 1, A and B) , indicating that the abnormal T cell activation in B6.NZBc1L mice results from an intrinsic T cell defect.
In contrast to the findings observed for T cells, the proportions of CD69 (Fig. 1, D-F B6 ϩ B6.Thy1 a IgH a bone marrow chimeric mice. Furthermore, the levels of autoantibodies produced were comparable to those seen in 16-wk-old B6.NZBc1L mice. Characterization of the origin of these Abs using allotype specific Abs revealed that only "b" allotype IgG2a anti-ssDNA ( p Ͻ 0.05) and -chromatin ( p Ͻ 0.005) Abs were produced (Fig. 2B) (Fig. 3, D-F) . Because the majority of PNA ϩ cells within the germinal centers were IgM a and IgM b negative (Fig. 3, D-F sections with anti-CD21 and anti-IgG2a a or IgG2a b to determine whether the germinal center B cells had undergone class-switching. As shown in Fig. 3 , G-I, the majority of germinal centers (60%) contained large numbers of IgG2a b cells, and these were found within both the PNA ϩ and PNA Ϫ populations. In contrast, no IgG2a a cells could be seen in any of the germinal centers of B6.NZBc1L ϩ B6.Thy1 a IgH a chimeric mice. Taken together, these findings indicate that B6.NZBc1L B cells have an intrinsic functional defect that leads to enhanced recruitment of these cells into autoreactive germinal centers and permits class switching of autoreactive B cells.
Increased activation of histone-reactive CD4
ϩ T cells in B6.NZBc1L and B6.NZBc1S mice B6.NZBc1S and B6.NZBc1L mice produce significantly elevated levels of IgG anti-chromatin Abs (18) . Because histone-reactive T cells have been shown to provide support for IgG anti-chromatin Ab production (23, 24), we investigated whether histone-reactive T cells were activated in B6.NZBc1S and B6.NZBc1L mice. To this end, chromosome 1 congenic and control mice were aged to 8 mo, and their splenic CD4 ϩ T cells were purified by negative selection. The purified T cells were then incubated with irradiated T cell-depleted B6 APCs together with various concentrations of purified bovine H1, H2A, H2B, H3, H4 or total histones, and T cell activation quantified by measurement of cytokine secretion and proliferation.
As shown in Fig. 4A , T cells from both B6.NZBc1L and B6.NZBc1S mice demonstrated increased production of IFN-␥ as compared with B6 T cells for virtually all of the histones tested. This achieved statistical significance in B6.NZBc1L mice with H1 ( p Ͻ 0.05) and H3 ( p Ͻ 0.05) stimulation and in B6.NZBc1S mice with total histone ( p Ͻ 0.05) and H2A ( p Ͻ 0.05) stimulation. In contrast, no IL-4 was elaborated following stimulation with any of the histones tested (data not shown). This did not reflect a general inability of these mice to produce IL-4 because IL-4 could be readily detected in the supernatants of wells stimulated with anti-CD3 or Con A, and the levels of these cytokines were comparable in all three strains (data not shown).
In contrast to the findings for cytokine secretion, significant Agspecific proliferation following stimulation with histones was seen only for B6.NZBc1L mice, with CD4 ϩ T cells from B6.NZBc1L mice demonstrating significantly increased proliferation in response to stimulation with total histones ( p ϭ 0.0005), H2B ( p Ͻ 0.0001), and H3 ( p Ͻ 0.05) (Fig. 4B) . T cells from B6.NZBc1L mice were not generally more hyperproliferative because these cells proliferated comparably to B6 and B6.NZBc1S cells in response to stimulation with Con A and anti-CD3. Although T cells from 8-mo-old B6.NZBc1S mice did not proliferate in response to histones, proliferation could be detected with T cells from 12-moold mice (data not shown). This finding suggests that differences between B6.NZBc1S and B6.NZBc1L mice at 8 mo of age reflect accelerated kinetics of the response in B6.NZBc1L mice rather than qualitative differences. Taken together, the data indicate that the lupus susceptibility locus located within the ϳ82-106 interval leads to activation of T cells specific for nucleosome histone components and that the susceptibility locus in ϳ35-82 interval serves to enhance this process.
Self-reactive B cells drive T cell activation in B6.NZBc1L but not B6.NZBc1S mice
We have shown previously that introduction of a nonself reactive Ig transgene recognizing hen egg white lysozyme (Ig Tg) onto the B6.NZBc1L background resulted in normalization of the B cell activation phenotype (18) , suggesting that the increased B cell activation in these mice reflects enhanced activation of self-reactive B cells. As a result of this constriction of the B cell repertoire, the proportions of activated (CD69 ϩ ) and memory (CD44 high CD62L low ) CD4 ϩ T cells in B6.NZBc1L Ig Tg mice were significantly reduced, indicating that autoreactive B cells were amplifying T cell activation. However, the proportion of memory T cells in B6.NZBc1L Ig Tg mice was not normalized to levels seen in B6 Ig Tg mice but remained significantly elevated at levels comparable to those seen in B6.NZBc1S non-Tg mice. This suggested that the increased activation of T cells observed in B6.NZBc1S mice might be B cell independent. To address this question, the Ig Tg was backcrossed onto the B6.NZBc1S background.
As in our previous study, Ͼ95% of B cells in Ig Tg mice were HEL-specific (data not shown) and the proportion of activated B cells was normalized in B6.NZBc1L and B6.NZBc1S Ig Tg mice to levels seen in control B6 Ig Tg mice (Table II) . Consistent with our previous results, the proportions of CD69 ϩ and CD44
high CD62L low CD4 ϩ T cells in B6.NZBc1L mice were markedly reduced by introduction of the Ig Tg but remained elevated as compared with B6 Ig Tg mice at levels seen in non-Tg B6.NZBc1S mice (Fig. 5) . In contrast, introduction of the Ig Tg on the B6.NZBc1S background had no impact on T cell activation, with the proportion of memory T cells remaining significantly higher than corresponding B6 Ig Tg controls (Fig. 5) . These data indicate that T cell activation in B6.NZBc1L, but not B6.NZBc1S mice, is amplified by the presence of activated self-reactive B cells.
The increased B cell activation in B6.NZBc1L mice is T cell dependent, indicating the presence of a positive feedback loop
In NZB mice, one of the manifestations of polyclonal B cell activation is increased costimulatory molecule expression on diverse B cell subsets (25) . This phenotype is seen in 3-to 4-wk-old mice and is CD40L and T cell independent, suggesting that it arises from an intrinsic B cell defect (J. Wither, N. Chang, C. Loh, G. Bonventi, S. Henrichs, Y. Cai, G. Lajoie, V. Ray, and R. MacLeod, manuscript in preparation; our unpublished observations). In B6.NZBc1L mice, increased costimulatory molecule expression does not develop until ϳ4 mo of age and, as outlined above, is most marked in the CD21 low B cell subset. Because of these differences, we were interested in determining whether the B cell activation phenotype in these mice is similarly T cell-independent. Therefore, we crossed a TCR␣-chain knockout onto the B6.NZBc1L genetic background and assessed B cell costimulatory molecule expression in 4-to 6-mo-old mice using flow cytometry.
Comparison of B cell costimulatory molecule expression on the CD21 low B cell population of B6.NZBc1L.TCR␣ ϩ/Ϫ and B6.NZBc1L.TCR␣ Ϫ/Ϫ mice revealed that B7.1 ( p Ͻ 0.0001) and B7.2 ( p Ͻ 0.001) were significantly reduced in knockout mice (Fig. 6) . Although there was a trend to decreased ICAM-1 expression, this did not achieve statistical significance. Similar findings were observed for CD69 expression in the total B cell population (%B cells CD69 ϩ/Ϫ mice, and there was no impact of the TCR knockout on this expression (data not shown). The proportion of B cells in peripheral B cell subsets as defined by staining with anti-CD21 and -CD23 was also unaffected by the TCR knockout (data not shown).
Despite decreased costimulatory molecule expression in the CD21 low subset of B6.NZBc1L.TCR␣ Ϫ/Ϫ mice, B7.1 remained elevated in this subset relative to B6.TCR␣ Ϫ/Ϫ mice ( p Ͻ 0.0005). It is likely that this residual B cell activation results from activation by the few residual T cells in these mice. Both B6.TCR␣ Ϫ/Ϫ and B6.NZBc1L.TCR␣ Ϫ/Ϫ mice had small populations of T cells that 
Discussion
Congenic mice are excellent tools for dissecting the complex genetic basis of murine SLE. To define the functional defects associated with the development of autoimmunity on NZB chromosome 1, we generated mice with short and long chromosome intervals. In our previous study, we provided evidence for at least two genetic loci on chromosome 1. One located within the ϳ82-106 cM interval affecting T cell activation and the second within the ϳ35-to 82 cM interval that appears to affect B cell activation and leads to enhanced autoantibody production, glomerulonephritis, splenomegaly, and T cell activation (18) . In the present study, we have demonstrated that the altered T and B cell activation in these mice results from intrinsic T and B cell functional defects and provide insight into the nature and location of these defects together with their role in the development of autoimmunity.
Although our mixed chimeric experiments used B6.NZBc1L bone marrow cells, our findings permit localization of intrinsic B and T cell defects not only to the B6.NZBc1L interval (ϳ35-106 cM) but also to the B6.NZBc1S interval (ϳ82-106 cM). In B6.NZBc1S mice, autoimmunity is characterized by production of IgG anti-ssDNA and -chromatin Abs. We show that production of these autoantibodies is critically dependent on the presence of an intrinsic B cell defect. Similarly, the increased proportion of CD4 ϩ memory T cells, a phenotype localized to the B6.NZBc1S interval, is restricted to congenic T cells in B6.NZBc1L ϩ B6.Thy1 a IgH a mixed chimeric mice. We further characterized this T cell defect by demonstrating that the abnormal T cell activation in B6.NZBc1S mice is B cell independent and associated with priming of IFN-␥-producing T cells with specificity for nucleosome histone components. Thus, in B6.NZBc1S mice, an intrinsic T cell defect that leads to abnormal activation of histone-reactive T cells and an intrinsic B cell defect that permits the abnormal differentiation of autoreactive B cells into Ab-producing cells act together to produce autoimmunity.
Our data also provides insight into how the additional susceptibility allele(s) in B6.NZBc1L mice leads to enhancement of autoimmunity. Using B6.NZBc1L ϩ B6.Thy1 a IgH a chimeric mice we show that enhanced up-regulation of costimulatory molecules, a phenotype that we have localized to the ϳ35-82 interval, reflects an intrinsic B cell defect. We further demonstrate that the upregulation of costimulatory molecules in B6.NZBc1L B cells is T cell dependent and requires IgR engagement, suggesting that selfreactive B cells in these mice have altered responses to T cell help. In support of this concept, we have found that B6.NZBc1L anti-HEL Ig Tg B cells demonstrate enhanced differentiation to Abproducing cells following transfer into B6.NZBc1L soluble HEL recipient mice (N.-H. Chang and J. E. Wither, unpublished observations). The more robust T cell activation in B6.NZBc1L, as compared with B6.NZBc1S, mice appears to be driven by interactions with these functionally altered self-reactive B cells, and it is probable that the enhanced histone-specific proliferative response of B6.NZBc1L T cells is due to the same process.
Despite the presence of activated self-reactive congenic B cells in B6.NZBc1L ϩ B6.Thy1 a IgH a mixed chimeric mice, activation of B6 T cells is not elevated above that seen in B6 ϩ B6.Thy1 a IgH a mixed chimeric mice. This observation suggests that the ability of B cells to drive T cell activation is dependent on the presence of an intrinsic T cell defect. Thus, in B6.NZBc1L mice, interactions between at least two independent susceptibility loci lead to a positive feedback loop in which functionally altered T cells activate functionally altered B cells and vice versa, resulting in amplification of the autoimmune phenotype. These data provide an important experimental confirmation of the role of selfreinforcing B and T cell interactions in the pathogenesis of lupus, as originally proposed by Shlomchik et al. (28) .
The lack of autoantibodies of B6 origin in B6.NZBc1L ϩ B6.Thy1 a IgH a chimeric mice suggests that activation of histonereactive T cells in these mice is insufficient to break tolerance to chromatin. This finding contrasts with previous work indicating that anergic chromatin/dsDNA-reactive B cells can become activated to enter germinal centers and differentiate into autoantibody producing cells, if provided with a source of cognate T cell help (29 -31) . It is possible that T cell help in B6.NZBc1L ϩ B6.Thy1 a IgH a chimeric mice differs qualitatively or quantitatively a IgH a chimeric mice. There are increasing data, from a variety of experimental systems, where generation of T reg cells has been impaired, implicating T reg cells in the regulation of lupus autoantibody production (26, 33) . In studies demonstrating a T cell-dependent loss of B cell tolerance to chromatin/ dsDNA by normal B cells, tolerant B cells were experimentally manipulated to present nonself-peptides to T cells, thus evading normal T cell tolerance mechanisms (30, 31) . In one of these experimental systems, addition of T reg cells prevented differentiation of chromatin/dsDNA B cells into Ab-forming cells as well as entry into germinal centers (31) . In B6.NZBc1L ϩ B6.Thy1 a IgH a chimeric mice, B6 B cells may be more susceptible than congenic B cells to the effects of this T reg -mediated inhibition.
The preferential ability of congenic B cells to be recruited into autoreactive germinal centers and differentiate into autoantibodyforming cells in B6.NZBc1L ϩ B6.Thy1 a IgH a chimeric mice suggests that these B cells have an intrinsic defect that disturbs tolerance. B cell tolerance to chromatin and dsDNA is maintained by multiple central and peripheral tolerance mechanisms, including clonal deletion, receptor editing, clonal anergy, follicular exclusion, down-regulation of the IgR, and germinal center tolerance mechanisms (34 -37 In normal mice dsDNA-and chromatin-reactive B cells that have evaded central deletion or editing are rendered anergic and/or down-regulate their IgRs (34 -36) . Although these cells can be recruited into germinal centers, in unmanipulated nonautoimmune mice they fail to differentiate into autoantibody-producing cells, undergo class-switching, or develop into memory cells (35) . In vitro anergic B cells demonstrate impaired responses to IgR engagement (38, 39) . For example, anergic B cells do not up-regulate costimulatory molecules following IgR cross-linking. It has been proposed this reduced expression of costimulatory molecules results in reduced T cell costimulation leading to decreased cytokine production and ineffective T cell help (40) . Our results demonstrating differential expression of costimulatory molecules, but not CD69, on congenic, as compared with B6, B cells in B6.NZBc1L ϩ B6.Thy1 a IgH a chimeric mice, suggest that self-reactive congenic B cells may be "less" anergic than their B6 counterparts. As a consequence of reduced anergy, congenic B cells may more effectively activate self-reactive T cells leading to enhanced cytokine production and support for entry into germinal centers, Ab production, and class-switching.
The T cell-and IgR-dependent enhanced expression of costimulatory molecules in B6.NZBc1L mice was most marked in the CD21 low B cell subset. Although transitional, CD5 ϩ , and germinal center B cells, as well as, plasmablasts, are found in the CD21 low B cell subset, analysis of this subset in B6.NZBc1L mice has revealed that the majority of these cells are transitional and germinal center B cells (Y.-H. Cheung and J. E. Wither, unpublished observations). The increased proportion of CD21 low B cells that we have previously identified in B6.NZBc1L mice is due to an increased number of germinal center B cells accumulating in this compartment and these cells have high levels of costimulatory molecules (data not shown). Therefore, it is probable that the increased proportion of congenic CD21 low B cells with high levels of costimulatory molecules in B6.NZBc1L ϩ B6.Thy1 a IgH a chimeric mice reflects increased recruitment of these cells into germinal centers. Although we also noted a trend to increased expression of B7.1 on AA4.1 ϩ IgM b , as compared with IgM a , immature B cells in these mice (data not shown).
Several candidate genes have been proposed for the ϳ82-106 cM interval found in B6.NZBc1S mice. These include Ifi202, Fcgr2b, and the SLAM/CD2 gene cluster (14 -17) . Ifi202, a transcriptional regulator, has been proposed to promote the development of autoimmunity in NZB chromosome 1 congenic mice through impaired B cell apoptosis (14) . As outlined above, our data are not consistent with a central B cell deletion defect. Furthermore, although we can readily demonstrate reduced apoptosis of NZB transitional B cells following IgM cross-linking, this process was normal in B6.NZBc1L mice (Ref. 50 and data not shown) Thus, if Ifi202 promotes autoimmunity in NZB mice, it is probable that it does so through some other mechanism.
A promoter polymorphism of the Fcgr2b gene, which leads to decreased expression of Fc␥RIIB on germinal center B cells, has also been proposed to promote autoantibody production in NZB mice (15, 16) . However, recent work indicates that the Fc␥RIIB receptor has little impact on germinal center selection mechanisms and instead appears to play an important role in providing a negative feedback signal to germinal center B cells limiting progression of class-switched B cells to plasma cells (41) . Therefore, it is unlikely that the B cell tolerance defect in B6.NZBc1L and B6.NZBc1S mice is due solely the Fcgr2b polymorphism in this interval.
Extensive polymorphisms in the SLAM/CD2 gene cluster were identified in B6.Slel congenic mice, with an introgressed NZW chromosome 1 interval, and proposed as candidate genes for the NZM mouse strain (17) . NZB mice have the same SLAM/CD2 haplotype and likely share the same T cell signaling abnormality as this strain. It should be noted that B6.Sle1 mice have a similar T cell activation phenotype to B6.NZBc1S mice, with a B cell-independent increase in T cell activation and evidence of spontaneous priming of histone-reactive T cells (21, 42) . However, recent work suggests that in B6.Sle1 mice this phenotype is derived from the Sle1a and Sle1c loci, and not the SLAM/CD2 cluster-containing Sle1b locus (43) . Thus, B6.NZBc1S mice may share more than one susceptibility allele with B6.Sle1 mice. If this is the case, then the most likely additional susceptibility allele is Sle1a because the polymorphism in Cr2 that has been proposed as a strong candidate gene for Sle1c is not found in NZB mice (44) . Aberrant activation of B cells with increased IL-6 secretion, STAT3/SOCS activation, and ras/MAPK activation has also been described for B6.Sle1ab mice (45) . The impact of these signaling abnormalities on B cell tolerance is currently unclear, but our data suggest that it is likely that similar abnormalities are present in B6.NZBc1S mice. Ongoing experiments in the laboratory are seeking to determine which aspects of the B cell tolerance defect that we have described for B6.NZBc1L B cells can be localized to the ϳ82-106 interval.
Although no candidate genes have been proposed for the ϳ35-82 interval, this interval contains a number of potential candidates including bcl-2, ship, and several tyrosine-phosphatase genes and regulators of G-protein signaling. Subcongenic mice are currently being generated to more precisely locate the region containing the susceptibility gene within this interval before further investigation of these genes.
The data outlined in this study clearly demonstrate that intrinsic B and T cell defects must act in concert to produce the autoimmune phenotype in B6.NZBc1L and B6.NZBc1S mice. They further indicate that epistatic genetic interactions can occur when functionally abnormal B and T cells interact with each other producing a positive feedback loop. Notably, humans with lupus share many of the features of B6.NZBc1L mice, including activation of histone-reactive B cells, increased B cell costimulatory molecule expression, and increased recruitment of B cells into germinal centers (46 -49) . Therefore, it is tempting to speculate that similar functional abnormalities will be required for the development of human SLE.
